The Nasaleze story all began one day in 1990...
Mike James was working in a factory making cosmetic facemasks for a well-known British healthcare product retailer using a number of ingredients. Mike noticed that despite there usually being clouds of white powder in the air nobody ever sneezed.
At the same time his teenage son was suffering terribly from allergies, sneezing almost constantly. Mike’s wife asked he do something about their son’s condition, under pressure Mike’s mind was cast back to the clouds of white powder in the factory. The following day he brought home some of this (cellulose) powder and suggested his sneezing son should ‘sniff’ some of the powder off the back of his hand.
|
 |
The effect was like switching off a light
The sneezing stopped in a matter of seconds and all the other symptoms subsided over the next few minutes. Mike was astonished by the effect and realized he had discovered something.
Mike immediately set about researching and developing his idea, including creating the unique and patented special delivery system. After the initial research proved encouraging Mike was ready to bring his invention to market.
However, the Medicines Control Agency (as it was known at the time) had other ideas, claiming that Mike was illegally producing a pharmaceutical product and that he should stop immediately.
Undeterred, Mike went about proving that his product was natural and not a drug. In order to get the Medicines Control Agency to approve Mike invoked the help of a political friend, Sir Teddy Taylor MP.
In the UK there is a weekly opportunity for a Member of Parliament to ask the Prime Minister a question in the House of Commons, known as Prime Minister’s Question Time. Upon Mike’s request, Sir Teddy Taylor asked the Prime Minister why Mr. James was being prevented from manufacturing and selling his natural allergy product. After this the Medicines Control Agency were forced to look into the issue in greater detail and came to the conclusion that Nasaleze was in fact a low risk product, not a drug and that it should be registered as a Class 1 Medical Device under EU Directive 93/42/EEC.
From humble beginnings
Nasaleze is now distributed in over 50 countries worldwide and is gaining respect from the Medical Community after successive and successful clinical studies.
|
|
 |
|
|
